Trade Organogenesis Holdings Inc. - ORGO CFD

Add to favourite

2.83

1.06%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Organogenesis Holdings Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	2.84
Open*	2.83
1-Year Change*	42.93%
Day's Range*	2.81 - 2.88
52 wk Range	1.80-4.71
Average Volume (10 days)	935.86K
Average Volume (3 months)	20.54M
Market Cap	500.44M
P/E Ratio	38.75
Shares Outstanding	132.04M
Revenue	449.01M
EPS	0.10
Dividend (Yield %)	N/A
Beta	1.52
Next Earnings Date	Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	2.84	0.10	3.65%	2.74	2.85	2.74
Apr 17, 2024	2.77	-0.05	-1.77%	2.82	2.89	2.75
Apr 16, 2024	2.84	0.11	4.03%	2.73	2.88	2.69
Apr 15, 2024	2.74	-0.10	-3.52%	2.84	2.89	2.74
Apr 12, 2024	2.86	-0.07	-2.39%	2.93	2.99	2.77
Apr 11, 2024	2.98	0.08	2.76%	2.90	3.00	2.90
Apr 10, 2024	2.93	0.20	7.33%	2.73	2.94	2.73
Apr 9, 2024	2.90	-0.05	-1.69%	2.95	3.04	2.86
Apr 8, 2024	2.95	0.14	4.98%	2.81	3.00	2.81
Apr 5, 2024	2.81	0.08	2.93%	2.73	2.87	2.69
Apr 4, 2024	2.77	0.02	0.73%	2.75	2.89	2.69
Apr 3, 2024	2.75	0.20	7.84%	2.55	2.76	2.52
Apr 2, 2024	2.59	-0.15	-5.47%	2.74	2.74	2.52
Apr 1, 2024	2.78	-0.04	-1.42%	2.82	2.82	2.68
Mar 28, 2024	2.81	0.10	3.69%	2.71	2.84	2.70
Mar 27, 2024	2.73	0.10	3.80%	2.63	2.74	2.58
Mar 26, 2024	2.60	0.00	0.00%	2.60	2.65	2.56
Mar 25, 2024	2.59	0.00	0.00%	2.59	2.66	2.56
Mar 22, 2024	2.58	-0.02	-0.77%	2.60	2.67	2.53
Mar 21, 2024	2.64	-0.15	-5.38%	2.79	2.82	2.62

Organogenesis Holdings Inc. Events

Time (UTC)	Country	Event
Wednesday, May 8, 2024
Time (UTC) 20:00	Country US	Event Q1 2024 Organogenesis Holdings Inc Earnings Release Q1 2024 Organogenesis Holdings Inc Earnings Release Forecast - Previous -
Wednesday, June 12, 2024
Time (UTC) 15:00	Country US	Event Organogenesis Holdings Inc Annual Shareholders Meeting Organogenesis Holdings Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, August 7, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Organogenesis Holdings Inc Earnings Release Q2 2024 Organogenesis Holdings Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	450.893	468.059	338.298	260.981	193.449
Revenue	450.893	468.059	338.298	260.981	193.449
Total Operating Expense	428.589	397.024	309.352	292.697	247.1
Selling/General/Admin. Expenses, Total	283.808	250.2	204.193	200.088	161.961
Operating Income	22.304	71.035	28.946	-31.716	-53.651
Net Income Before Taxes	20.282	63.786	17.764	-38.559	-64.747
Net Income After Taxes	15.532	94.902	17.234	-38.709	-64.831
Net Income Before Extra. Items	15.532	94.902	17.234	-38.709	-64.831
Net Income	15.532	94.902	17.234	-38.709	-64.831
Income Available to Common Excl. Extra. Items	15.532	94.902	17.234	-39.277	-64.831
Income Available to Common Incl. Extra. Items	15.532	94.902	17.234	-39.277	-64.831
Diluted Net Income	15.532	94.902	17.234	-39.277	-64.831
Diluted Weighted Average Shares	132.383	133.663	111.361	92.8404	69.3185
Diluted EPS Excluding Extraordinary Items	0.11733	0.71001	0.15476	-0.42306	-0.93526
Diluted Normalized EPS	0.13045	0.74204	0.14058	-0.41002	-0.91562
Interest Income (Expense), Net Non-Operating	-2.009	-7.236	-11.279	-6.856	-11.258
Total Adjustments to Net Income		0	0	-0.568
Cost of Revenue, Total	105.019	114.199	87.319	75.948	68.808
Gross Profit	345.874	353.86	250.979	185.033	124.641
Research & Development	39.762	30.742	20.086	14.799	10.742
Interest Expense (Income) - Net Operating					3.494
Unusual Expense (Income)	0	1.883	-2.246	1.862	2.095
Other, Net	-0.013	-0.013	0.097	0.013	0.162
Minority Interest					0

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	117.316	107.642	115.516	116.859	121.401
Revenue	117.316	107.642	115.516	116.859	121.401
Cost of Revenue, Total	26.316	26.607	27.11	26.177	26.652
Gross Profit	91	81.035	88.406	90.682	94.749
Total Operating Expense	107.571	111.643	106.798	115.08	109.466
Selling/General/Admin. Expenses, Total	70.443	73.834	68.293	79.328	72.609
Research & Development	10.938	11.202	11.395	9.575	10.205
Unusual Expense (Income)	-0.126		0	0
Operating Income	9.745	-4.001	8.718	1.779	11.935
Interest Income (Expense), Net Non-Operating	-0.594	-0.649	0.03	-0.572	-0.73
Other, Net	0.028	0.023	0.006	0.005	-0.021
Net Income Before Taxes	9.179	-4.627	8.754	1.212	11.184
Net Income After Taxes	5.316	-2.969	7.486	0.215	8.744
Net Income Before Extra. Items	5.316	-2.969	7.486	0.215	8.744
Net Income	5.316	-2.969	7.486	0.215	8.744
Income Available to Common Excl. Extra. Items	5.316	-2.969	7.486	0.215	8.744
Income Available to Common Incl. Extra. Items	5.316	-2.969	7.486	0.215	8.744
Diluted Net Income	5.316	-2.969	7.486	0.215	8.744
Diluted Weighted Average Shares	133.066	131.084	131.867	132.233	132.601
Diluted EPS Excluding Extraordinary Items	0.03995	-0.02265	0.05677	0.00163	0.06594
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	0.0394	-0.01319	0.06163	0.00463	0.06973

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	222.609	226.979	174.344	125.6	71.131
Cash and Short Term Investments	102.478	113.929	84.394	60.174	21.291
Cash	102.478	113.929	84.394	60.174	21.291
Prepaid Expenses	5.086	4.969	4.935	2.953	2.328
Total Assets	449.359	443.259	294.494	220.687	163.678
Other Long Term Assets, Total	31.534	33.531	0.688	1.011	0.817
Total Current Liabilities	75.023	82.005	68.217	59.894	66.388
Accrued Expenses	38.155	48.374	23.973	23.45
Notes Payable/Short Term Debt	0	0	0	0	2.545
Other Current Liabilities, Total	0	1.436	0.578	5	37.177
Total Liabilities	183.69	201.224	148.41	165.104	116.637
Total Long Term Debt	66.231	70.769	64.486	97.549	49.216
Other Liabilities, Total	42.436	48.45	15.707	7.661	1.033
Total Equity	265.669	242.035	146.084	55.583	47.041
Common Stock	0.013	0.013	0.013	0.01	0.009
Additional Paid-In Capital	310.957	302.155	299.129	226.58	177.272
Retained Earnings (Accumulated Deficit)	-45.301	-60.133	-153.058	-171.007	-130.24
Total Liabilities & Shareholders’ Equity	449.359	443.259	294.494	220.687	163.678
Total Common Shares Outstanding	130.919	128.68	127.732	104.871	91.2614
Preferred Stock - Non Redeemable, Net		0
Total Receivables, Net	89.45	82.46	56.804	39.359	34.077
Accounts Receivable - Trade, Net	89.45	82.46	56.804	39.359	34.077
Total Inventory	24.783	25.022	27.799	22.918	13.321
Other Current Assets, Total	0.812	0.599	0.412	0.196	0.114
Property/Plant/Equipment, Total - Net	145.655	128.304	60.068	47.184	39.623
Goodwill, Net	28.772	28.772	28.772	25.539	25.539
Intangibles, Net	20.789	25.673	30.622	20.797	26.091
Note Receivable - Long Term			0	0.556	0.477
Accounts Payable	32.33	29.339	23.381	28.387	19.165
Current Port. of LT Debt/Capital Leases	4.538	2.856	20.285	3.057	7.501
Long Term Debt	66.231	70.769	53.044	83.118	39.062
Capital Lease Obligations		0	11.442	14.431	10.154
Property/Plant/Equipment, Total - Gross	208.453	186.033	129.589	112.996
Accumulated Depreciation, Total	-62.798	-57.729	-69.521	-65.812

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	225.573	216.435	216.822	222.609	230.526
Cash and Short Term Investments	98.226	88.917	88.694	102.478	107.25
Cash	98.226	88.917	88.694	102.478	107.25
Total Receivables, Net	89.276	93.615	92.021	89.45	93.115
Accounts Receivable - Trade, Net	89.276	93.615	92.021	89.45	93.115
Total Inventory	27.905	25.364	25.539	24.783	24.683
Prepaid Expenses	9.567	7.948	9.847	5.086	4.707
Other Current Assets, Total	0.599	0.591	0.721	0.812	0.771
Total Assets	462.647	450.313	446.107	449.359	457.272
Property/Plant/Equipment, Total - Net	159.866	155.369	149.476	145.655	142.381
Property/Plant/Equipment, Total - Gross	230.109	223.086	214.966	208.453	204.419
Accumulated Depreciation, Total	-70.243	-67.717	-65.49	-62.798	-62.038
Goodwill, Net	28.772	28.772	28.772	28.772	28.772
Intangibles, Net	17.101	18.33	19.56	20.789	22.01
Other Long Term Assets, Total	31.335	31.407	31.477	31.534	33.583
Total Current Liabilities	81.482	73.455	76.076	75.023	89.273
Accounts Payable	26.784	27.39	30.31	32.33	37.952
Accrued Expenses	48.041	40.376	40.757	38.155	46.317
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	6.657	5.689	5.009	4.538	5.004
Other Current Liabilities, Total				0	0
Total Liabilities	185.782	179.031	182.406	183.69	200.944
Total Long Term Debt	64.283	63.891	64.86	66.231	67.6
Long Term Debt	62.117	63.489	64.86	66.231	67.6
Capital Lease Obligations	2.166	0.402
Other Liabilities, Total	40.017	41.685	41.47	42.436	44.071
Total Equity	276.865	271.282	263.701	265.669	256.328
Common Stock	0.013	0.013	0.013	0.013	0.013
Additional Paid-In Capital	317.254	314.838	312.573	310.957	309.102
Retained Earnings (Accumulated Deficit)	-40.402	-43.569	-48.885	-45.301	-52.787
Total Liabilities & Shareholders’ Equity	462.647	450.313	446.107	449.359	457.272
Total Common Shares Outstanding	131.313	131.312	131.226	130.919	130.915
Preferred Stock - Non Redeemable, Net	0	0	0		0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	15.532	94.902	17.234	-40.454	-64.831
Cash From Operating Activities	24.859	61.978	5.466	-33.528	-60.739
Changes in Working Capital	-34.082	-37.71	-27.757	-9.667	-22.401
Cash From Investing Activities	-33.898	-31.22	-23.498	-6.234	-1.856
Other Investing Cash Flow Items, Total		0	-5.82	0	0.001
Cash From Financing Activities	-2.199	-1.036	42.468	78.727	81.642
Financing Cash Flow Items	-1.256	-1.22	55.556	46.443	80.347
Issuance (Retirement) of Stock, Net	2.07	2.198	2.823	0.897	0.119
Issuance (Retirement) of Debt, Net	-3.013	-2.014	-15.911	31.387	1.176
Net Change in Cash	-11.238	29.722	24.436	38.965	19.047
Non-Cash Items	30.701	26.032	7.694	7.051	19.329
Cash From Operating Activities	5.845	5.781	4.438	3.388	3.309
Amortization	4.883	4.949	3.745	6.043	3.669
Deferred Taxes	1.98	-31.976	0.112	0.111	0.186
Capital Expenditures	-33.898	-31.22	-17.678	-6.234	-1.857
Cash Taxes Paid	1.201	0.607	0.061	0.049
Cash Interest Paid	2.649	5.787	9.609	8.148

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-2.969	15.532	8.046	7.831	0.087
Cash From Operating Activities	-5.077	24.859	17.059	11.606	1.411
Cash From Operating Activities	2.694	5.845	4.331	2.875	1.347
Amortization	1.23	4.883	3.662	2.442	1.221
Non-Cash Items	5.795	30.701	23.822	12.698	5.654
Cash Taxes Paid	-0.128	1.201	-0.974	0.974	0.004
Cash Interest Paid	1.271	2.649	1.787	1.041	0.627
Changes in Working Capital	-11.827	-34.082	-22.802	-14.24	-6.898
Cash From Investing Activities	-7.562	-33.898	-23.242	-12.84	-6.672
Capital Expenditures	-7.562	-33.898	-23.242	-12.84	-6.672
Cash From Financing Activities	-1.236	-2.199	-0.324	-0.35	-0.765
Financing Cash Flow Items	-0.298	-1.256	-1.256	-1.254	-0.488
Issuance (Retirement) of Stock, Net	0	2.07	2.07	2.042	0.291
Issuance (Retirement) of Debt, Net	-0.938	-3.013	-1.138	-1.138	-0.568
Net Change in Cash	-13.875	-11.238	-6.507	-1.584	-6.026
Other Investing Cash Flow Items, Total
Deferred Taxes		1.98

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Organogenesis Holdings Inc. Company profile

About Organogenesis Holdings Inc

Organogenesis Holdings Inc. is a regenerative medicine company, which is focused on the development, manufacture, and commercialization of solutions for the wound care and surgical and sports medicine markets. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.

Financial summary

BRIEF: For the nine months ended 30 September 2021,Organogenesis Holdings Inc revenues increased 47% to$339.5M. Net income totaled $43.2M vs. loss of $545K.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Basic Earnings per Share excluding Extraordinary Itemsincreased from -$0.01 to $0.34.

Industry:

Biotechnology & Medical Research (NEC)

85 Dan Rd
CANTON
MASSACHUSETTS 02021-2810
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024